|
KMID : 0606920120200030256
|
|
Biomolecules & Therapeutics
2012 Volume.20 No. 3 p.256 ~ p.267
|
|
|
Tamoxifen Resistance in Breast Cancer
|
|
Chang Min-Sun
|
|
|
Abstract
|
|
|
|
Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer. The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor. This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clinical values and issues of tamoxifen use, and molecular mechanisms of tamoxifen resistance. Emerging knowledge on the molecular mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.
|
|
|
KEYWORD
|
|
|
Breast cancer, Estrogen receptor, Tamoxifen, Antiestrogen resistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|